HUMAN MEDICINES EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR): BLINCYTO, BLINATUMOMAB, PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA, DATE OF AUTHORISATION: 23/11/2015, REVISION: 11, STATUS: AUTHORISED
(AGENPARL) – LONDON (UNITED KINGDOM), sab 23 gennaio 2021 The most common side effects with Blincyto (which may affect more than 1 in 10 people) are infections, fever, infusion-related reactions (like fever, changes in blood pressure and rash), headache, febrile neutropenia (low levels a type of white blood cell counts......